TRPV1-mediated Pharmacological Hypothermia Promotes Improved Functional Recovery Following Ischemic Stroke

Area of Science:

• Neuroscience
• Pharmacology
• Stroke Research

Background:

• Current hypothermia strategies for stroke neuroprotection have limitations due to side effects.
• Pharmacological hypothermia is being explored as a safer alternative for stroke treatment.
• Activation of the TRPV1 channel by DHC induces reliable hypothermia.

Purpose of the Study:

• To investigate the long-term effects of DHC-induced hypothermia on ischemic stroke injury.
• To evaluate the impact of TRPV1-mediated hypothermia on functional outcomes post-stroke.

Main Methods:

• Administered DHC to induce hypothermia 3.5 hours after stroke induction in mice.
• Assessed primary cortical and secondary thalamic injury.
• Utilized diffusion tensor imaging (DTI) to evaluate thalamic fiber integrity.
• Monitored behavioral recovery for one month post-stroke.

Main Results:

• DHC-induced hypothermia significantly reduced primary cortical injury.
• A 53% reduction in thalamic lesion size was observed in DHC-treated mice.
• DHC treatment decreased neuronal loss, astrogliosis, and thalamic fiber loss.
• A single 8-hour DHC treatment led to long-term functional recovery and improved behavioral outcomes.

Conclusions:

• TRPV1-mediated hypothermia effectively reduces both acute and remote ischemic brain injury.
• Single DHC treatments yield persistent improvements in functional recovery after stroke.
• TRPV1 agonism presents a promising therapeutic strategy for stroke treatment.